These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 27738284)

  • 1. Impact of rapid molecular diagnostic tests on time to treatment initiation and outcomes in patients with multidrug-resistant tuberculosis, Tamil Nadu, India.
    Nair D; Navneethapandian PD; Tripathy JP; Harries AD; Klinton JS; Watson B; Sivaramakrishnan GN; Reddy DS; Murali L; Natrajan M; Swaminathan S
    Trans R Soc Trop Med Hyg; 2016 Sep; 110(9):534-541. PubMed ID: 27738284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural setting: a cohort study in South Africa's Eastern Cape Province.
    Iruedo J; O'Mahony D; Mabunda S; Wright G; Cawe B
    BMC Infect Dis; 2017 Jan; 17(1):91. PubMed ID: 28109255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How has the Zimbabwe mycobacterial culture and drug sensitivity testing system among re-treatment tuberculosis patients functioned during the scale-up of the Xpert MTB/RIF assay?
    Timire C; Takarinda KC; Harries AD; Mutunzi H; Manyame-Murwira B; Kumar AMV; Sandy C
    Trans R Soc Trop Med Hyg; 2018 Jun; 112(6):285-293. PubMed ID: 29992299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of reliance on Xpert MTB/RIF on time to treatment and multidrug-resistant tuberculosis treatment outcomes in Tanzania: a retrospective cohort study.
    Mollel E; Lekule I; Lynen L; Decroo T
    Int Health; 2019 Nov; 11(6):520-527. PubMed ID: 30806660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved treatment outcome of multidrug-resistant tuberculosis with the use of a rapid molecular test to detect drug resistance in China.
    Shi W; Davies Forsman L; Hu Y; Zheng X; Gao Y; Li X; Jiang W; Bruchfeld J; Diwan VK; Hoffner S; Xu B
    Int J Infect Dis; 2020 Jul; 96():390-397. PubMed ID: 32353546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid molecular diagnostics for multi-drug resistant tuberculosis in India.
    Ramachandran R; Muniyandi M
    Expert Rev Anti Infect Ther; 2018 Mar; 16(3):197-204. PubMed ID: 29406800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathways to multidrug-resistant tuberculosis diagnosis and treatment initiation: a qualitative comparison of patients' experiences in the era of rapid molecular diagnostic tests.
    Naidoo P; van Niekerk M; du Toit E; Beyers N; Leon N
    BMC Health Serv Res; 2015 Oct; 15():488. PubMed ID: 26511931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Xpert MTB/RIF assay on multidrug-resistant tuberculosis treatment outcomes in a health district in South Africa.
    Mahwire TC; Zunza M; Marukutira TC; Naidoo P
    S Afr Med J; 2019 Mar; 109(4):259-263. PubMed ID: 31084692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of the INNO-LiPA Rif. TB® line-probe assay in rapid detection of multidrug-resistant tuberculosis in Latvia.
    Skenders GK; Holtz TH; Riekstina V; Leimane V
    Int J Tuberc Lung Dis; 2011 Nov; 15(11):1546-52, i. PubMed ID: 22008771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant clinical impact of a rapid molecular diagnostic test (Genotype MTBDRplus assay) to detect multidrug-resistant tuberculosis.
    Kipiani M; Mirtskhulava V; Tukvadze N; Magee M; Blumberg HM; Kempker RR
    Clin Infect Dis; 2014 Dec; 59(11):1559-66. PubMed ID: 25091301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Xpert® MTB/RIF assay in routine diagnosis of pulmonary tuberculosis: A multicentre study in Lithuania.
    Pimkina E; Zablockis R; Nikolayevskyy V; Danila E; Davidaviciene E
    Respir Med; 2015 Nov; 109(11):1484-9. PubMed ID: 26403251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of GenoType® MTBDRplus assay to assess drug resistance and mutation patterns of multidrug-resistant tuberculosis isolates in northern India.
    Maurya AK; Singh AK; Kant S; Umrao J; Kumar M; Kushwaha RA; Nag VL; Dhole TN
    Indian J Med Microbiol; 2013; 31(3):230-6. PubMed ID: 23883707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.
    Evans D; Schnippel K; Govathson C; Sineke T; Black A; Long L; Berhanu R; Rosen S
    PLoS One; 2017; 12(7):e0181238. PubMed ID: 28746344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early detection of multi-drug resistance and common mutations in Mycobacterium tuberculosis isolates from Delhi using GenoType MTBDRplus assay.
    Singhal R; Myneedu VP; Arora J; Singh N; Bhalla M; Verma A; Sarin R
    Indian J Med Microbiol; 2015 Feb; 33 Suppl():46-52. PubMed ID: 25657156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid diagnosis of tuberculosis and multidrug resistance by the microscopic-observation drug-susceptibility assay.
    Shah NS; Moodley P; Babaria P; Moodley S; Ramtahal M; Richardson J; Heysell S; Li X; Moll A; Friedland G; Sturm AW; Gandhi NR
    Am J Respir Crit Care Med; 2011 May; 183(10):1427-33. PubMed ID: 21297071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unacceptable treatment outcomes and associated factors among India's initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007-2011): Evidence leading to policy enhancement.
    Parmar MM; Sachdeva KS; Dewan PK; Rade K; Nair SA; Pant R; Khaparde SD
    PLoS One; 2018; 13(4):e0193903. PubMed ID: 29641576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Xpert® MTB/RIF diagnosed disseminated smear-negative MDR-TB in a sub-district hospital in India.
    Dorjee K; Salvo F; Dierberg KL
    Int J Tuberc Lung Dis; 2012 Nov; 16(11):1560-1. PubMed ID: 23044453
    [No Abstract]   [Full Text] [Related]  

  • 18. Diagnostic performance of the Xpert MTB/RIF assay for tuberculous lymphadenitis on fine needle aspirates from Ethiopia.
    Biadglegne F; Mulu A; Rodloff AC; Sack U
    Tuberculosis (Edinb); 2014 Sep; 94(5):502-5. PubMed ID: 24931451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gridlock from diagnosis to treatment of multidrug-resistant tuberculosis in Tanzania: low accessibility of molecular diagnostic services and lack of healthcare worker empowerment in 28 districts of 5 high burden TB regions with mixed methods evaluation.
    Mpagama SG; Mbelele PM; Chongolo AM; Lekule IA; Lyimo JJ; Kibiki GS; Heysell SK
    BMC Public Health; 2019 Apr; 19(1):395. PubMed ID: 30971228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Molecular Drug Susceptibility Testing on the Time to Multidrug-resistant Tuberculosis Treatment Initiation.
    Jeon D; Kang H; Kwon YS; Yim JJ; Shim TS
    J Korean Med Sci; 2020 Sep; 35(35):e284. PubMed ID: 32893517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.